On 2 December 2025, CHS announced it had completed the sale of select “ambulatory outreach laboratory services” to Labcorp for approximately US$ 194 million in cash (before transaction costs).  The transaction encompasses patient-service centres and in-office phlebotomy locations in 13 U.S. states.

Under the agreement, Labcorp assumes those assets and associated leases and will integrate them into its diagnostic network. CHS, for its part, will continue operating its inpatient and emergency-department labs, and maintain lab services for hospital-based testing such as pre-admission testing, imaging, and other core hospital diagnostics. 

CHS’s leadership said the divestiture aligns with its strategy to focus on core hospital services aiming to improve patient experience by leveraging Labcorp’s scale and expertise in diagnostic services, data analytics, and digital tools. Meanwhile, Labcorp stated the acquisition will strengthen its outreach lab footprint and broaden access to its comprehensive lab testing capabilities to communities served by former CHS outpatient labs. 

Industry analysts see this transaction as part of a broader trend: major health-systems divesting outpatient diagnostics while specialized national labs consolidate to deliver high-volume, standardized testing and advanced diagnostics.